Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Key takeaways
- Life Biosciences is testing its ER-100 drug, which the company claims has restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year.
- It will be targeting patients with glaucoma and NAION, two conditions that cause damage to crucial cells in the optic nerve, which transmits visual information from the back of the eye to the brain.
- Aging biology—understanding how the body’s cells and functions deteriorate over time—is at the root of longevity science.
Why this matters: a development in AI with implications for how people work, create, and decide.
Photo-Illustration: WIRED Staff; Getty Images Comment Loader Save Story Save this story Comment Loader Save Story Save this story. A longevity startup has dosed its first patient with a drug to reverse age-related sight loss.
Life Biosciences is testing its ER-100 drug, which the company claims has restored vision in monkeys, for safety and side effects in a study of around 18 adults over the next year.
It will be targeting patients with glaucoma and NAION, two conditions that cause damage to crucial cells in the optic nerve, which transmits visual information from the back of the eye to the brain. ER-100 is designed to rejuvenate those cells so that they work again and restore sight.